PXAI Audio Feed
08/04 11:15 defenseworld.net

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $242.00 at Citigroup

Neurocrine BiosciencesNBIXtarget priceCitigroupbuy ratingCanaccord Genuity
07/04 12:21 yahoo.com

Neurocrine to acquire Soleno in $2.9bn transaction

Neurocrine BiosciencesSoleno Therapeuticsacquisition$2.9bnneurodegenerative diseasetherapeutics
06/04 20:13 barrons.com

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play.

Soleno TherapeuticsNeurocrine$2.9B buyoutweight‑loss drugappetite suppressantstock surge
06/04 20:06 yahoo.com

Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share

Soleno TherapeuticsNeurocrine$2.9B buyoutall‑cash acquisitionstock surgeneurotherapeutics
06/04 18:21 inc.com

Neurocrine Is Making a $2.9 Billion Bet on a New Kind of Drug

NeurocrineSoleno TherapeuticsPrader‑Willi syndromerare diseasedrug acquisition$2.9B investment
06/04 16:51 statnews.com

STAT+: Pharmalittle: We’re reading about an FDA delay forcing a biotech to close, a Neurocrine deal, and more

FDAbiotechNeurocrineKezar Life Sciencesclinical trialrare disease
06/04 16:13 statnews.com

STAT+: Stealth biotech Stipple bets on secretive ADCs

small biotechFDA delaysNeurocrineSoleno TherapeuticsPrader‑WilliNIH budget cuts
06/04 14:12 investing.com

Neurocrine to buy Soleno Therapeutics for $2.9 billion

Neurocrine TherapeuticsSoleno Therapeuticsacquisition$2.9 billionneurodegenerative diseasesrare disease therapies
06/04 14:04 marketwatch.com

Neurocrine wants to develop new obesity drugs. It’s reportedly nearing an acquisition to accelerate that move.

NeurocrineSoleno Therapeuticsobesity drugsacquisitionbiotechstock surge
06/04 14:04 marketwatch.com

Neurocrine wants to develop new obesity drugs. It’s reportedly nearing an acquisition to accelerate that move.

NeurocrineSoleno Therapeuticsobesity drugsacquisitionbiotechstock surge
Comments
Loading...
0